IndiaCatalog.com
Login Signup
IndiaCatalog.com
Home Web Directory Classifieds Yellow Pages Global Directory City Guide News Photo Galleries
Login
Signup
  • Home
  • Global Web Directory
  • Drugs
Biotechnology
Diagnostic Substances
Drug Delivery
Drug Manufacturers - Major
Drug Manufacturers - Other
Drug Related Products
Drugs - Generic

Pharsight Corporation

Pharsight Corporation

Pharsight wants to shorten the path to market for tomorrow's pharmaceutical breakthroughs. The company's software and consulting services aim to take some of the guesswork out of the drug development process for pharmaceutical and biotech firms, helping them choose the most promising drug candidates, to design effective clinical trials, and to keep up with regulatory reporting. Pharsight's WinNonlin and WinNonMix applications, for instance, analyze research and clinical data to help companies develop appropriate dosing regimens for clinical trials. And its consulting services help them make key strategy decisions about the future of development programs. Pharsight was acquired by Tripos in 2008.

NutraCea

NutraCea

NutraCea is a health science company that has intellectual property that allows the Company to process and convert rice bran into a nutritious ingredient, stabilized rice bran that has applications in various food products and as components of formulations that have applications for treatment modalities in nutritional supplementation. It is also used as a stand-alone product that can be sold through non-related entities with distribution into the market place, both in the United States and internationally. These products include food supplements and medical foods. The Company operates in two segments: the NutraCea segment, which manufactures and distributes ingredients primarily derived from SRB, and the Irgovel segment, which consists of its rice-bran oil and fatted and de-fatted SRB manufacturing subsidiary in Pelotas, Brazil. In November 2009, the Company filed a voluntary petition for protection under Chapter 11 of the United States Bankrupt Code.

FibroGen, Inc.

FibroGen, Inc.

FibroGen, Inc. company is focused on developing and commercializing treatments for fibrosis, anemia, diabetes, and cancer, as well as producing recombinant human collagens and synthetic gelatins. FibroGen has several products in clinical development, including: FG-3019, a monoclonal antibody that may treat a variety of conditions including diabetic nephropathy; FG-2216, an orally administered small molecule drug in development for the treatment of anemia; FG-5017, a recombinant version of human collagen; and FG-5009, a synthetic gelatin molecule designed to stabilize vaccines and biologics. The company commenced lab operations in 1995.

ChemoCentryx, Inc.

ChemoCentryx, Inc.

ChemoCentryx is focused exclusively on the discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemoattractant receptors. Since its founding, ChemoCentryx has established one of the broadest pipelines of chemokine-based therapeutics in the pharmaceutical industry. This has been based on our pioneering insight into the chemokine system, a complex network of chemokine (CHEMO-attractant cytoKINE) molecules (ligands) and receptors that work together to regulate the movement of immune cells in and out of inflamed tissues. Each of our novel small molecule product candidates is designed to target a specific chemokine or chemoattractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

CyDex Pharmaceuticals, Inc.

CyDex Pharmaceuticals, Inc.

CyDex Pharmaceuticals, Inc. company was founded in 1993 and is based in Lenexa, Kansas. CyDex Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of drugs specifically designed to address limitations of current therapies. It develops a portfolio of product candidates utilizing its drug formulation technology using Captisol, a group of cyclodextrins. The company’s products include Geodon IM and Abilify Injection IM for bipolar disorder/schizophrenia; Vfend IV for antifungal; and Cerenia for canine motion sickness. It also develops Fosphenytoin IV and IM for status epilepticus; Melphalan IV for multiple myeloma; Topiramate IV for epilepsy; Amiodarone IV for arrhythmia; Budesonide Solution Inhalation for asthma; Clopidogrel IV for atherothrombosis; and Budesonide/Azelastine Nasal Spray for allergic rhinitis. In addition, the company out license its technology to third parties for use in the development of their products. CyDex Pharmaceuticals, Inc. was formerly known as CyDex, Inc. and it changed its name in November 2007.

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Birmingham, Alabama. BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The company has progressed two compounds into late-stage pivotal clinical trials comprising Peramivir, an anti-viral for influenza; and Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor forcutaneous T-cell lymphoma (CTCL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the United States Department of Health and Human Services (HHS).Forodesine has been granted Orphan Drug status by the FDA for three indications, including T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias, such as T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-ALL. BioCryst Pharmaceuticals is also testing BCX4208, a second generation PNP inhibitor, which is in a Phase II study for the treatment of gout. The company utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. It has strategic alliances with the U.S. Department of Health and Human Services; Shionogi & Co., Ltd.; Green Cross Corporation; and Mundipharma International Holdings Limited.

Discovery Laboratories, Inc.

Discovery Laboratories, Inc.

Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania. Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The company's proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

DFB Pharmaceuticals, Inc.

DFB Pharmaceuticals, Inc.

DFB Pharmaceuticals makes products that protect its armor -- the skin. Through its Healthpoint subsidiary, the pharmaceutical holding company develops, acquires, and markets drug brands that prevent or treat disorders associated with skin and soft tissue. Its portfolio of more than 50 prescription and over-the-counter (OTC) products includes dermatology creams, surgical scrubbing solutions, and wound cleansers and dressings. Its DPT Laboratories subsidiary offers contract manufacturing of semi-solid and liquid drugs, while Phyton Biotech produces active pharmaceutical ingredients (APIs) for DFB and other drug makers in the area of plant-cell culture technology.

Manhattan Pharmaceuticals, Inc.

Manhattan Pharmaceuticals, Inc.

Manhattan Pharmaceuticals, Inc. company was founded in 2001 and is based in New York, New York. Manhattan Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of pharmaceutical therapies in the United States. Its product candidates under development include Hedrin, a novel, non-insecticide treatment for pediculosis; and Topical PTH (1-34) for the treatment of psoriasis. Manhattan Pharmaceuticals has a joint venture agreement with Nordic Biotech Advisors ApS to develop and commercialize Hedrin.

Phase Bioscience, Inc.

Phase Bioscience, Inc.

Phase Bioscience is a biotechnology firm that has developed a technology utilizing genetically-engineered biopolymer peptides (ELPs) that changes solubility (from a liquid to a solid and back) based on the temperature and the salt content of the solution. Known as deltaPhase, Phase Bioscience's ELPs are designed to be used by pharmaceutical researchers in drug discovery processes and in life science applications, including recombinant protein purification (isolating a particular protein in a solution) and enzyme biocatalysts (isolating a particular recombinant enzyme in a solution).

Post a FREE Classified Advertisement

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.

Most Read News

IndiaCatalog News
Tata Communications, Tata Motors partner to launch 5G-powered Sierra.ev
IndiaCatalog News
Suzlon secures 250 MW wind energy order from Torrent Green Energy
IndiaCatalog News
DRDO cleared to transfer all conventional missile tech to pvt industry
IndiaCatalog News
Trump administration moves to impose over $100K fee on H-1B worker visas
IndiaCatalog News
Indian pharma firms have little reason to fear Trump's tariff threat

CORPORATE NEWS

Ashok Leyland Limited
Ashok Leyland Limited
Hindustan Motors Limited
Hindustan Motors Limited
IDEA Cellular Limited
IDEA Cellular Limited
Unitech Limited
Unitech Limited
Kotak Mahindra Group
Kotak Mahindra Group
Hyundai Motor India Ltd.
Hyundai Motor India Ltd.
Reliance Industries Limited (RIL)
Reliance Industries Limited (RIL)
Axis Bank
Axis Bank
IndiaCatalog.com

IndiaCatalog.com is a website brought to you by Portland Technologies to provide directory of Indian websites, News, City Guides and profiles of Indian Businesses. Portland Technologies also provides IT solutions for Small and Medium Businesses in India.


Products

India Web Directory

Global Web Directory

Yellow Pages

Photo Galleries

FREE India Classifieds


Useful links

About us

Advertise

Link to us

Submit a Site

Business Reviews


Contact

Plot #37, Ramnagar Gundu, Hyderabad - 500 044

service@indiacatalog.com

+91-40-23756949


© Copyright: IndiaCatalog.com